Pharmacokinetics of Quetiapine in Elderly Patients with Selected Psychotic Disorders
To assess the pharmacokinetics and tolerability of quetiapine in elderly patients with selected psychotic disorders.
This was a multicentre, open-label, 27-day, rising multiple-dose trial. Descriptive statistics summarised plasma quetiapine concentrations and pharmacokinetic parameters by trial day. A two-way analysis of variance was used to evaluate all pharmacokinetic parameters, and 90% confidence intervals of the mean differences were calculated.
Antipsychotic drugs taken prior to the study period were discontinued on day 1. Quetiapine treatment began on day 3. Doses were increased stepwise, starting at 25mg three times daily and reaching 250mg three times daily by day 21. Patients: Twelve patients (age 63–85 years) with schizophrenia, schizoaffective disorder or bipolar disorder.
Main outcome measures and results
Key assessments included quetiapine plasma concentrations, and neurological and safety evaluations. Under steady-state conditions, the 100 and 250mg doses of quetiapine were not significantly different in terms of dose-normalised area under the plasma concentration-time curve within an 8-hour dose administration interval, or in dose-normalised minimum plasma concentration (Cmin) at the end of a dose administration interval. The morning Cmin values for the seven discrete dose amounts evaluated also increased linearly with dose. The apparent oral clearance, volume of distribution and half-life did not change as a function of dose. There were no serious adverse events. The most common adverse events were postural hypotension (n = 6), dizziness (n = 5) and somnolence (n = 4).
While quetiapine was well tolerated at doses up to 250mg three times daily, the potential for reduced clearance, as well as the adverse effects of postural hypotension and dizziness, indicated that quetiapine should be introduced at lower doses and titrated at a relatively slower rate in patients ≥65 years.
- 1.Seroquel (quetiapine fumarate): full prescribing information. Wilmington (DE): AstraZeneca, 2004Google Scholar
- 13.Kane J, Woerner M, Lieberman J. Tardive dyskinesia incidence and risk factors. J Clin Psychopharmacol 1988; 8(4 Suppl.): 52–6Google Scholar
- 21.Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 2001; 23(11): 1839–54CrossRefPubMedGoogle Scholar
- 25.Diagnostic and statistical manual of mental disorders. 3rd ed. rev. Washington, DC: American Psychiatric Press, 1987Google Scholar
- 29.Guy W, editor. AIMS: ECDEU assessment manual for psychopharmacology. Rev. ed. Rockville (MD): US Department of Health, Education, and Welfare, 1976Google Scholar
- 31.CGI Clinical Global Impression. ECDEU assessment manual for psychopharmacology. Rev. ed. Rockville (MD): US Department of Health, Education, and Welfare, 1976Google Scholar
- 32.Andreasen N. Modified scale for the assessment of negative symptoms: NIMH treatment strategies in schizophrenia study. Washington, DC: Public Health Administration, US Department of Health and Human Services, 1984. Publication no. ADM 9-102Google Scholar